The Impact of Missing Vaccines on Africa and Asia

HIV/AIDS Africa

Picture 5 of 6

The battle against HIV and AIDS may well have died down in many ways in the west over the last decade, but the problem remains critical across many other parts of the world.

In the absence of a HIV vaccine, organisations such as WHO, UNAIDS and Médecins Sans Frontières have made a substantial impact on HIV in areas such as Africa and the SEAR through increasing the availability of anti-retrovirals and the implementation of structure and support for sufferers. New infection rates have droppedas low as 0.4% in tightly controlled communities.

But with massive social barriers still in the way of blanket coverage for HIV and AIDS, not to mention the high cost of supplying patients with a lifetime supply of ART, a HIV vaccine could provide better coverage for less money.

After early clinical trial disappointments (HVTN 5050 and RV144),There are a number of different HIV vaccines currently in clinical development: GeoVax Labs’ COVX-B11 produced promising results from a phase I study in January; and InnaVirVax SA’s VAC-3S is currently in phase II. The battle against HIV and AIDS may well have died down in many ways in the west over the last decade, but the problem remains critical across many other parts of the world.

In the absence of a HIV vaccine, organisations such as WHO, UNAIDS and Médecins Sans Frontières have made a substantial impact on HIV in areas such as Africa and the SEAR through increasing the availability of anti-retrovirals and the implementation of structure and support for sufferers. New infection rates have droppedas low as 0.4% in tightly controlled communities.

But with massive social barriers still in the way of blanket coverage for HIV and AIDS, not to mention the high cost of supplying patients with a lifetime supply of ART, a HIV vaccine could provide better coverage for less money.

After early clinical trial disappointments (HVTN 5050 and RV144),There are a number of different HIV vaccines currently in clinical development: GeoVax Labs’ COVX-B11 produced promising results from a phase I study in January; and InnaVirVax SA’s VAC-3S is currently in phase II. There has also been a recent flurry of grants awarded to biotechs developing HIV vaccines, including a $9.8 million grant given from the NIH to Seattle BioMed to develop a HIV/AIDS vaccine.

Tags: , , , , , , ,

About the Author

About the Author: Despite holding a degree in philosophy, I've a taste for the scientific and the experimental. With interests in innovation, experimentation and business strategy within the life sciences you will find me writing for Vaccine Nation, Total Orphan Drugs, and Total BioPharma .

Subscribe

If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on Google Plus Join Our LinkedIn Group Connect on YouTube

1 Reader Comment

Trackback URL Comments RSS Feed

  1. Rashika El Ridi says:

    I think that schistosomiasis is the real plague of African Countries, as beside its sequelae it deviates the immune system towards the type 2 arm, and thus predisposes the host to ill resistance against infection with malaria, hepatic and immunodeficiency viruses, and virulent bacteria. Yet, schistosomiasis is increasingly neglected. We have established at Cairo University a formula for a reproducibly effective vaccine for schistosomiasis and together with Professor John Dalton provided and published its application and proof of concept. We are looking forward to international scientific cooperation for going ahead with vaccine implementation instead of lamenting. Rashika El Ridi

Leave a Reply

Your email address will not be published. Required fields are marked *

Current ye@r *

Top
Geolocation